Theravance Biopharma TBPH Business Segments — Recurring Operating Expenses

Similar metrics at other companies

MCRISingle Reportable — Operating Costs And Expenses

$17.73M+4.7%

IOVASingle Reportable — Operating Expenses

$107.98M-12.1%

ALMSSingle Reportable — Operating Expenses

$100.15M-15.8%

MCRISingle Reportable — Operating Expenses

$108.96M+3.2%

IMNMSingle Reportable — Operating Expenses

-$59.33M-24.7%

MCRISingle Reportable — Other Cost And Expense Operating

$1.59M+237%

Questions, answered.

What is Theravance Biopharma's business segments — recurring operating expenses?

Theravance Biopharma (TBPH) reported business segments — recurring operating expenses of $23.55M in Q1 2026.

How has Theravance Biopharma's business segments — recurring operating expenses changed year-over-year?

Theravance Biopharma's business segments — recurring operating expenses decreased by 21.0% year-over-year, from $29.82M to $23.55M.

What is the long-term trend for Theravance Biopharma's business segments — recurring operating expenses?

Over 2 years (2023 to 2025), Theravance Biopharma's business segments — recurring operating expenses has grown at a 0.2% compound annual growth rate (CAGR), from $110.72M to $111.07M.

What does business segments — recurring operating expenses mean?

This measures the ongoing, predictable costs required to maintain daily business operations, excluding one-time or non-recurring charges. It provides a baseline for evaluating the company's long-term operational sustainability and burn rate.